Bozkurt Biykem, Coats Andrew Js, Tsutsui Hiroyuki, Abdelhamid Magdy, Adamopoulos Stamatis, Albert Nancy, Anker Stefan D, Atherton John, Böhm Michael, Butler Javed, Drazner Mark H, Felker G Michael, Filippatos Gerasimos, Fonarow Gregg C, Fiuzat Mona, Gomez-Mesa Juan-Esteban, Heidenreich Paul, Imamura Teruhiko, Januzzi James, Jankowska Ewa A, Khazanie Prateeti, Kinugawa Koichiro, Lam Carolyn S P, Matsue Yuya, Metra Marco, Ohtani Tomohito, Francesco Piepoli Massimo, Ponikowski Piotr, Rosano Giuseppe M C, Sakata Yasushi, SeferoviĆ Petar, Starling Randall C, Teerlink John R, Vardeny Orly, Yamamoto Kazuhiro, Yancy Clyde, Zhang Jian, Zieroth Shelley
J Card Fail. 2021 Mar 1. doi: 10.1016/j.cardfail.2021.01.022.
In this document, we propose a universal definition of heart failure (HF) as the following: HF is a clinical syndrome with symptoms and or signs caused by a structural and/or functional cardiac abnormality and corroborated by elevated natriuretic peptide levels and or objective evidence of pulmonary or systemic congestion. We propose revised stages of HF as follows. At-risk for HF (Stage A), for patients at risk for HF but without current or prior symptoms or signs of HF and without structural or biomarkers evidence of heart disease. Pre-HF (stage B), for patients without current or prior symptoms or signs of HF, but evidence of structural heart disease or abnormal cardiac function, or elevated natriuretic peptide levels. HF (Stage C), for patients with current or prior symptoms and/or signs of HF caused by a structural and/or functional cardiac abnormality. Advanced HF (Stage D), for patients with severe symptoms and/or signs of HF at rest, recurrent hospitalizations despite guideline-directed management and therapy (GDMT), refractory or intolerant to GDMT, requiring advanced therapies such as consideration for transplant, mechanical circulatory support, or palliative care. Finally, we propose a new and revised classification of HF according to left ventricular ejection fraction (LVEF). The classification includes HF with reduced EF (HFrEF): HF with an LVEF of ≤40%; HF with mildly reduced EF (HFmrEF): HF with an LVEF of 41% to 49%; HF with preserved EF (HFpEF): HF with an LVEF of ≥50%; and HF with improved EF (HFimpEF): HF with a baseline LVEF of ≤40%, a ≥10-point increase from baseline LVEF, and a second measurement of LVEF of >40%.
在本文件中,我们提出心力衰竭(HF)的通用定义如下:HF是一种临床综合征,由心脏结构和/或功能异常引起,伴有症状和/或体征,并通过利钠肽水平升高和/或肺或体循环充血的客观证据得到证实。我们提出如下修订后的HF阶段。HF风险期(A期),适用于有HF风险但目前或既往无HF症状或体征且无心脏病结构或生物标志物证据的患者。HF前期(B期),适用于目前或既往无HF症状或体征,但有结构性心脏病或心脏功能异常证据,或利钠肽水平升高的患者。HF(C期),适用于由心脏结构和/或功能异常引起的目前或既往有HF症状和/或体征的患者。晚期HF(D期),适用于静息时有严重HF症状和/或体征、尽管接受了指南指导的管理和治疗(GDMT)仍反复住院、对GDMT难治或不耐受、需要进行高级治疗(如考虑移植、机械循环支持或姑息治疗)的患者。最后,我们根据左心室射血分数(LVEF)提出了一种新的修订后的HF分类。该分类包括射血分数降低的HF(HFrEF):LVEF≤40%的HF;射血分数轻度降低的HF(HFmrEF):LVEF为41%至49%的HF;射血分数保留的HF(HFpEF):LVEF≥50%的HF;以及射血分数改善的HF(HFimpEF):基线LVEF≤40%、较基线LVEF升高≥10个百分点且第二次测量的LVEF>40%的HF。